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A 69-year-old woman with dyspepsia and poor oral in-
take was diagnosed as advanced gastric cancer. 
Clinical staging was stage IV with inoperable status, 
and thus, three cycles of palliative chemotherapy with 
paclitaxel and cisplatin were performed. Follow up en-
doscopy and positron emission tomography with com-
puted tomography (PET-CT) revealed marked de-
crease in the primary stomach lesion and metastatic 
lymph nodes. Distal gastrectomy and D2 lymph node 
dissection were performed with gastrojejunostomy. 
Later pathological examination demonstrated tumor in-
vading submucosa. However, there was no pathologic 
evidence of lymph node metastasis. Only the necrotic 
areas without viable carcinoma cells were noted in re-
gional lymph nodes located along the left gastric ar-
tery and common hepatic artery. Because of the ex-
cellent response to chemotherapy, R0 resection was 
carried out. Herein, we report a case of advanced 
gastric cancer showing complete remission of meta-
static lymphadenopathy after palliative chemotherapy. 
(Gut and Liver 2007;1:74-78)
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INTRODUCTION
  Advanced gastric cancer (AGC) is the second leading 
cause of death related to cancer in the world.1 Although 
surgery is the primary therapy for localized gastric cancer, 
only half of the patients with locally advanced gastric can-
cer, which comprises stages IIIA, IIIB and IV, can under-
go an R0 resection and extended surgery including D2 
dissection.2 Prognosis is usually dismal because only 33% 
of all stages are resectable.3 For unresectable gastric can-
cer, chemotherapy may have palliative effects in some 
patients. In four studies, combination chemotherapy re-
sulted in a better quality of life and overall survival when 
compared with the best supportive care in patients with 
unresectable advanced gastric cancer.4-6 Because curative 
resection is considered to be the best available therapy 
for gastric cancer, to achieve R0 resection in cases with 
locally advanced unresectable gastric cancer, down staging 
with preoperative chemotherapy followed by curative sur-
gery may be an effective treatment modality for patients 
with unresectable gastric cancer.4 A retrospective analysis 
of R0 resection was accomplished in 10 out of 27 pa-
tients with stage IV gastric cancer after undergoing pre-
operative S-1/DDP neoadjuvant chemotherapy.5 In three 
Japanese case reports, down staging and curative surgery 
was accomplished in three patients with stage IV gastric 
cancer after administration of paclitaxel combined with 
cisplatin, TS-1 or low dose 5-flurouracil.6-8 
  Herein, we report a case of stage IV gastric cancer, in 
which R0 resection and pathologic nodal complete re-
sponse were accomplished after chemotherapy with pacli-
taxel and cisplatin.3
CASE REPORT
  A 69-year-old woman was admitted to Severance Hospital 
because of dyspepsia and poor oral intake. Upper gastro-
intestinal endoscopy demonstrated an ulcerative lesion with 
irregular base, coated with dirty exudates from the pre-
pylorus to the angle of stomach (Fig. 1A). Endoscopic biop-
sy revealed poorly differentiated adenocarcinoma.
  Abdominal computed tomography (CT) showed massive 
lymphadenopathy at the left gastric, porta hepatis, porto-
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Fig. 1. Findings of upper gas-
trointestinal endoscopy. (A) Be-
fore chemotherapy, an ulcero-
fungating mass with nodular 
surface and exudate is noted on 
the angle and on the lesser 
curvature of antrum. (B) After 3 
cycles of chemotherapy, previ-
ously noted mass is replaced by 
slightly depressed mucosal les-
ion with scar. 
Fig. 2. (A) Abdominal computed tomography (CT) before treatment reveals multiple lymphadenopathy indicating lymph node 
metastases at the left gastric (left upper), porta hepatis, portocaval (right upper), peripancreatic, and omental lymph nodes (left 
lower). The primary cancer is invading the common hepatic artery (right lower). (B) PET-CT after 3 cycles of chemotherapy shows 
marked decrease in size of the perigastric and hepatoduodenal ligament lymph nodes when compared to those noted on the 
previous abdominal CT scan (black arrows). There is no increased FDG uptake in the stomach and lymph nodes at the perigastric 
and hepatoduodenal ligament areas.
caval, peripancreatic and omental lymph nodes indicating 
lymph node metastases, including common hepatic artery 
invasion of the primary cancer (Fig. 2A). Physical exami-
nation revealed no specific problems. Serum level of carci-
noembryonic antigen (CEA) was 166.5 ng/ml and that of 
the carbohydrate antigen (CA) 19-9 was 7.2 U/mL.
1. Neoadjuvant chemotherapy 
  The patient underwent combination chemotherapy for 
palliation, which consisted of three-week cycles of admin-
istration of cisplatin 75 mg/m2 as 2 hour infusion in 150 
mL of normal saline and paclitaxel 175 mg/m2 as 3 hour 
infusion in 500 mL of 5% DW. There was no side effect 
during and after the first and second cycle of chemo-
therapy. However, grade 4 neutropenia (390/uL) and 
grade 4 nausea, vomiting, and hyponatremia developed af-
ter the third cycle of chemotherapy. After the completion 
of three cycles of chemotherapy, follow-up gastrointestinal 
endoscopy demonstrated slightly depressed mucosal le-
sion with white atrophic changes and visible submucosal 
vessels in the previously noted ulcerative area. Marginal 
folds were slightly edematous (Fig. 1B). 
  Positron emission tomography with computed tomog-
raphy (PET-CT) scanning did not identify the primary 
stomach cancer definitely. In addition, the size of the per-
igastric and hepatoduodenal ligament lymph nodes were 
markedly decreased when compared with the previous ab-
dominal CT scan. Furthermore, there was no increased 
fluorodeoxyglucose (FDG) uptake in the stomach and 
lymph nodes at the perigastric and hepatoduodenal liga-
ment areas (Fig. 2B). 
2. Intraoperative findings
  Surgery was recommended since the primary cancer and 
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Fig. 3. Gross finding of the surgical specimens. The stomach 
measures 22 cm along the greater curvature and 13.5 cm along the
lesser curvature. There is an ill-defined pale nodular area on the 
serosal surface. The stomach is incised along the greater curvature,
and there is an ill-defined shallow depressed lesion, measuring 
2.5×2 cm. The main lesion is located in the lesser curvature side 
of the antrum. It is located 4.5 cm apart from the proximal 
resection margin and 5.5 cm apart from the distal resection 
margin. The remaining mucosa is slightly edematous. 
Fig. 4. Microscopic findings. (A) At low magnification, the antral mucosa is infiltrated with adenocarcinoma extending down to the
submucosal layer. (B) At high magnification, the tumor glands show moderate differentiation without definite lymphovascular 
permeation or perineural invasion. (C) Immunohistochemical stain with cytokeratin reveals positive in tumor cells. The tumor 
glands are extending to the upper submucosa (sm1, invasion depth: 0.1 cm). (D) The enlarged lymph nodes are totally replaced by 
tumor necrosis. There is no viable tumor cell in the resected specimen.
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metastatic lymph nodes showed marked decrease in size 
on the PET-CT scan. A subtotal gastrectomy and D2 
lymph node dissection, including regional lymph nodes 
along the left gastric artery, common hepatic artery, and 
celiac artery were done. Complete omentectomy was per-
formed with a gastrojejunostomy. The stomach was dif-
fusely edematous and fragile. There was neither organ in-
vasion nor peritoneal seeding. There was no palpable le-
sion in the rectal shelf during the surgical procedure. 
3. Histological diagnosis 
  Gross examination demonstrated an ill-defined pale 
nodular area on the serosal surface of the stomach. When 
the specimen was opened along the greater curvature, an 
ill-defined, shallow depressed lesion was noted at the 
lesser curvature side of the antrum (Fig. 3). The remain-
ing mucosa was slightly edematous. 
  Microscopic findings revealed a moderately differen-
tiated tubular adenocarcinoma invading submucosa, which 
was detected by immunohistochemical staining for CK 
(AE1/AE2). The depth of the submucosa invasion was 
0.1 cm (Fig. 4A-C). A total of 20 lymph nodes were dis-
sected and evaluated by histological examination. There 
was no microscopic lymph node metastasis. However, ne-
crotic areas without viable carcinoma cells were noted in 
No 1 (perigastric lymph node along lesser curvature), No 
4 (perigastric lymph node along greater curvature), No 5 
(perigastric lymph node along lesser curvature), No 7 
(lymph nodes along left gastric artery), and No 8 (lymph 
nodes along common hepatic artery) regions, suggesting 
degeneration of the cancer cells (Fig. 4D). The final histo-
logical staging was T1bN0M0. The postoperative serum 
CEA level was 5.66 ng/mL. The patient was discharged 
without any postoperative complications and was followed 
up in the outpatient department without additional post-
operative chemotherapy. 
DISCUSSION
  In the present case, palliative chemotherapy was per-
formed. Response to the chemotherapy was so dramatic 
that it resulted in a down staging of the cancer leading to 
R0 resection with pathologic nodal complete remission 
(CR). Two similar cases were reported in Japan. A case 
with pathologic nodal CR after two courses of chemo-
therapy with paclitaxel and TS-1 for AGC was reported.7 
The patient had left gastric artery lymph node metastasis 
with invasion to the pancreas and spleen.7 Another case 
showed disappearance of the primary lesion and partial 
response of the metastatic lymph nodes in a AGC patient 
with peritoneal seeding after two cycle of paclitaxel and 
low dose FP (5-fluorouracil and cisplatin) chemotherapy.8 
  Taxanes (paclitaxel and docetaxel), irinotecan and ox-
aliplatin are relatively new agents used for gastric cancer 
which demonstrated a significant activity against gastric 
cancer. Paclitaxel is approved in Korea as a first-line 
treatment for AGC. In a randomized phase II clinical trial 
performed in a single center, paclitaxel combined with 
5FU showed a 42% response rate in metastatic gastric 
cancers which were naive to chemotherapy.9 
  It is uncommon to achieve resectability and nodal re-
sponse after neoadjuvant chemotherapy in an unresectable 
AGC. A number of case reports on stage IV gastric can-
cers showed good response to chemotherapy consisting of 
TS-1. In their report, chemotherapy enabled possible radi-
cal resection.10-13 Therefore, it has been reported that this 
treatment strategy may improve the prognosis in patients 
with AGC. 
  Recently, three large phase III trials were being con-
ducted to assess the usefulness of neoadjuvant chemo-
therapy. The MAGIC trial in the UK compared surgery 
alone with ECF (epirubicin, cisplatin, and 5-fluorouracil). 
A multinational European trial (EORTC 40954) compared 
surgery alone with surgery after neoadjuvant PLF (cispla-
tin, leucovorin, and 5-fluorouracil). A Swiss study (SAKK 
43/99) compared surgery plus preoperative TCF (taxo-
tere, cisplatin, and 5-fluorouracil) with surgery followed 
by the same chemotherapy regimen.14,15 Most of these 
clinical trials included patients with resectable AGC.
  As mentioned above, fifty percent of cases were diag-
nosed initially as over stage III disease. Only 33% of all 
cases are candidates for surgical resection. For patients 
with unresectable AGC without distant metastasis, issue 
is not whether to treat with neoadjuvant chemotherapy, 
but rather to choose the best chemotherapeutic agents 
which result in down staging so that R0 resection could 
be performed in unresectable AGC patients. Further in-
vestigation is needed to compare the rate and degree of 
response to various chemotherapeutic protocols. In addi-
tion, important factors that improve outcomes in AGC 
need to be investigated.
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